$1.44 -0.05 (-3.36%)
11/6/2009 4:00 PM

AVI BioPharma, Inc. (AVII)

CAPS Rating: 4 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

Current Price $1.44 Mkt Cap $123.45M
Open $1.49 P/E Ratio 0.00
Prev. Close $1.49 Div. (Yield) N/A (N/A)
Daily Range $1.40 - $1.54 Volume 1,357,656
52-Wk Range $0.45 - $2.73 Avg. Daily Vol. 2,650,000

AVII News and Commentary

Caps

This ticker is not currently Ratable.

Add Stock to Watchlist

All Members

126 Outperform
12 Underperform
 

All-Star Members

26 Outperform
3 Underperform
 

Wall Street

2 Outperform
1 Underperform
 

Top AVII Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

em5 (< 20)
Submitted February 11, 2007

Aiming towards some pretty big markets .At the moment though, still slogging it's way through ph I/II trials and anyone who follows Pharma or biotech knows that 90% of new drugs end up down the drain. I'm not letting that little fact deter me from… More

0 Comments | Reply | Report this Post

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

AVII VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about AVII.

Recs

0
Member Avatar mjrruby (< 20) Submitted: 10/6/2009 4:04:11 PM : Outperform Start Price: $1.81 AVII Score: -22.21

Just read Barons issue of Oct.5, 2009

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar EnigmaDude (37.84) Submitted: 10/5/2009 2:46:08 PM : Outperform Start Price: $1.95 AVII Score: -28.99

Barrons write-up and today got approval for Junin virus drug.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar rofgile (88.85) Submitted: 10/4/2009 12:33:49 PM : Outperform Start Price: $1.58 AVII Score: -9.61

RNAI was a big technology for basic lab research in the 2000's. I was fairly doubtful, and still am, that this is a practical technology able to deliver interfering RNA to cells in a human body - it is difficult enough to deliver it to cells in a petri dish. They have a novel form of an RNAI inhibitor, it is not antisense RNA, which is what we all used. Instead it is a mimicing compound - that is why I am giving this an upthumb. I still think its crazy, but I don't think it is impossible. If it works, this company will be a leader in drug development.

Report this Post 0 Comments | Reply | Permalink
View All 27 Pitches »

Leaderboard

Find the members with the highest scoring picks in AVII.

Score Leader

TrackJimCramer

TrackJimCramer (< 20) Score: +67.40

The Score Leader is the member with the highest score across all their picks in AVII.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
Longorshort25 65.48 8/6/2009 Underperform 5Y $2.20 -34.55% +7.75% +42.30
Made4WallStreet 72.39 12/29/2006 Underperform 1Y $3.23 -55.42% -19.95% +35.47
SCOTTinKY < 20 12/29/2006 Underperform 3Y $3.19 -54.86% -19.92% +34.94
DrBigGun 33.13 2/21/2007 Underperform 1Y $2.93 -50.85% -21.91% +28.94
proud174 73.95 2/20/2007 Underperform 3M $2.91 -50.52% -21.88% +28.63
dirtball410 93.41 3/13/2007 Underperform 1Y $2.51 -42.63% -18.88% +23.75
Krimes < 20 3/13/2007 Underperform 5Y $2.51 -42.63% -18.88% +23.75
1under5out 87.88 7/20/2007 Underperform 5Y $2.83 -49.12% -27.19% +21.92
honcharella 88.83 3/23/2007 Underperform 3Y $2.47 -41.70% -21.02% +20.68
BreakerDc 50.93 3/20/2007 Underperform 3Y $2.39 -39.75% -19.20% +20.55
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackRodmanRen < 20 8/13/2007 Outperform NS $2.89 -50.17% -23.02% -27.15
TrackMaximGroup < 20 3/30/2007 Outperform NS $2.53 -43.08% -20.38% -22.71
TrackJimCramer < 20 3/15/2006 Underperform 3W $6.95 -79.28% -11.88% +67.40

Featured Broker Partners